Year: 2021
Radium Podcast interview with BerGenBio CEO Richard Godfrey, hosted by RADFORSK
Bergen, Norway, 17 February 2021 - In this Radium podcast interview with RADFORSK, BerGenBio CEO Richard Godfrey…
Read MoreBERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2020
Bergen, Norway, 10 February 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for…
Read MoreSECOND DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF BERGENBIO’S BGBC020 TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS
Bergen, Norway, 8th February 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBERGENBIO PRESENTS UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC AT WCLC 2020
· Bemcentinib in combination with pembrolizumab was well-tolerated and showed promising clinical activity in refractory…
Read MoreBERGENBIO ASA: INVITATION TO FOURTH QUARTER 2020 RESULTS
Bergen, Norway, 27 January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBERGENBIO TO PRESENT UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC AT WCLC 2020
· Bemcentinib in combination with pembrolizumab was well-tolerated and showed promising clinical activity in refractory…
Read More
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159